logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Phosphodiesterase 4 Inhibitor class drugs

    FiltersReset Filters
    6 results

    • daliresp

      (roflumilast)
      AstraZeneca Pharmaceuticals LP
      Usage: DALIRESP® is indicated for reducing the risk of COPD exacerbations in patients with severe COPD linked to chronic bronchitis and a history of exacerbations. It is not a bronchodilator and should not be used for acute bronchospasm relief. The initial dose is 250 mcg for the first four weeks only.

    • eucrisa

      (crisaborole)
      Pfizer Laboratories Div Pfizer Inc
      Usage: EUCRISA is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients aged 3 months and older.

    • otezla

      (apremilast)
      Amgen Inc
      Usage: OTEZLA is indicated for treating adult patients with active psoriatic arthritis, adults and pediatric patients (ages 6+, ≥20 kg) with moderate to severe plaque psoriasis, and adults with oral ulcers associated with Behçet's Disease.

    • roflumilast

      (Roflumilast)
      MAJOR PHARMACEUTICALS
      Usage: Roflumilast Tablets are indicated for reducing COPD exacerbation risk in patients with severe COPD and chronic bronchitis. It is not a bronchodilator and is not intended for acute bronchospasm relief. The starting dose is 250 mcg for the first four weeks and is not the therapeutic dose.

    • zoryve

      (roflumilast)
      Arcutis Biotherapeutics, Inc.
      Usage: ZORYVE® foam, 0.3%, is indicated for treating seborrheic dermatitis in adults and pediatric patients aged 9 years and older.

    • zoryve

      (roflumilast)
      Arcutis Biotherapeutics, Inc.
      Usage: ZORYVE® cream is indicated for the topical treatment of plaque psoriasis in patients aged 6 and older, including intertriginous areas, and for mild to moderate atopic dermatitis in the same age group.